Generalized form and duration of myasthenia gravis as predictors of cognitive impairment
https://doi.org/10.33667/2078-5631-2020-22-60-64
Abstract
We performed a clinical, neurological, neuropsychological and laboratory examination of 30 patients with a confirmed diagnosis of myasthenia gravis, aged 25 to 69 years (49.0 ± 14.6 years), 11 men and 19 women. Among the examined patients, the generalized form of myasthenia was diagnosed in 20 (66.7%) patients: 4 (20.0%) cases of severe and 16 (80.0%) of moderate forms. The ocular form of myasthenia was found in 10 (33.3%) cases. Neuropsychological testing revealed memory impairment in 15 (50.0%), attention – 11 (36.7%), emotional disturbances – 13 (43.3%) patients with myasthenia gravis. A significant decrease in the concentration of brain-derived neurotrophic factor (BDNF) in the blood serum of patients with myasthenia was noted, compared with the control group (p < 0.01). When comparing the data of neuropsychological testing, the level of BDNF and the history of the disease, it was found that patients with a generalized form of myasthenia gravis and a disease duration of more than three years have a lower level BDNF, which has a reliable correlation with lower cognitive function scores.
About the Authors
S. A. Nalkin
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
M. G. Sokolova
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
S. V. Lobzin
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
V. L. Kokorenko
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
N. V. Vasileva
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
E. V. Frolova
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
O. V. Aak
North-Western State Medical University n.a. I.I. Mechnikov
Russian Federation
Russian Federation
Saint Petersburg
References
1. Агафонов Б.В., Котов С.В., Сидорова О.П. Миастения и врожденные миастенические синдромы. М.: МИА, 2013. 244 с.
2. Sherifa A.H., Ahmad H.Y., Mohamad A. Abd El H. et al. Assessment of cognitive function in patients with myasthenia gravis. Neuroimmunol Neuroinflammation, Vol 1, Issue 3, Dec, 2014. P. 141–146. DOI: 10.4103/2347–8659.143671.
3. Налькин С.А., Лобзин С.В., Соколова М.Г. Особенности когнитивных функций у пациентов с миастенией // Медицинский академический журнал. 2018. Т. 18. № 3. С. 41–45. DOI: 10.17816/MAJ18341–45.
4. Kaltsatou A., Fotiou D., Tsiptsios T. et al. Cognitive impairment as a central cholinergic deficit in patients with Myasthenia Gravis // BBA Clinical Vol. 3, June 2015, P. 299–303. DOI: 10.1016/j.bbacli.2015.04.003. PMID: 26672759.
5. Cuello A. C. Basal Forebrain Cholinergic Neurons // Encyclopedia of Psychopharmacology. Springer Berlin Heidelberg, 2010. P. 201.
6. Левин О.С. Диагностика и лечение деменции в неврологической практике. 4-е издание. М. МЕДпресс-информ, 2014. 256 с.
7. Woolf N. J., Butcher L. L. Cholinergic systems mediate action from movement to higher consciousness // Behavioural brain research. 2011. Vol. 221. N 2. P. 488–498. DOI: 10.1016/j.bbr.2009.12.046. PMID: 20060422.
8. Полунина А. Г., Брюн Е. А. Эпизодическая память: неврологические и нейромедиаторные механизмы // Анналы клинической и экспериментальной неврологии. 2012. Т. 6. № 3. С. 53–60.
9. Соколова М.Г., Алексеева Т.М., Лобзин С.В. и др. Нейротрофические факторы. Перспективы применения в клинической неврологии // Вестник Северо-Западного гос. мед. университета им. И.И. Мечникова. 2014. Т. 6, № 3. С. 75–81.
10. Попова Н. К., Ильчибаева Т. В., Науменко В. С. Нейротрофические факторы и серотонинергическая система мозга обзор // Биохимия. 2017. Т. 82. № 3. С. 449–459. DOI: 10.1134/S0006297917030099. PMID: 28320272.
11. Острова, И.В., Голубева, Н.В., Кузовлев, А.Н. и др. Прогностическая значимость и терапевтический потенциал мозгового нейротрофического фактора BDNF при повреждении головного мозга (обзор) // Общая реаниматология. 2019. Т. 15. № 1. DOI: 10.15360/1813–9779–2019–1–70–86.
12. Leal G., Afonso P.M., Salazar I. L. et al. Regulation of hippocampal synaptic plasticity by BDNF // Brain research. 2015. Vol. 1621. P. 82–101. DOI: 10.1016/j.brainres.2014.10.019. PMID: 25451089.
13. Kimura A., Namekata K., Guo X. et al. Neuroprotection, growth factors and BDNF-TrkB signaling in retinal degeneration // International journal of molecular sciences. 2016. Vol. 17. № 9. P. 1584. DOI: 10.3390/ijms17091584. PMID: 27657046.
14. Соколова М. Г., Лобзин С. В., Литвиненко И. В. и др. К вопросу о патогенезе когнитивных расстройств при мышечной дистрофии Дюшенна в клинико-лабораторном и молекулярно-генетическом исследовании // Журнал неврологии и психиатрии им. С. С. Корсакова. 2017. 117 (12). С. 78. № 84. DOI: 10.17116/jnevro201711712178–84.
15. Белоусова Н. П., Громова О. А., Пепеляев Е. Г. и др. Взаимосвязь когнитивных нарушений и уровня BDNF у лиц молодого возраста // Медицина в Кузбассе. 2017. № 4. С. 39–43.
16. Соколова М. Г., Лобзин С.В., Лопатина Е.В. и др. Роль ростовых полипептидных соединений в механизме пластичности ЦНС у больных наследственной патологией периферического двигательного нейрона // Биомедицинская химия. 2017. Т. 63, вып. 5. С. 453–456. DOI: 10.18097/PBMC20176305453.
17. Hempstead B. L. Brain-derived neurotrophic factor: three ligands, many actions // Transactions of the American Clinical and Climatological Association. 2015. Vol. 126. P. 9. PMID: 26330656.
18. Соколова М. Г., Лобзин С. В., Резванцев М. В. Особенности нейротрофической регуляции у больных спинальной мышечной атрофией 2-го типа // Нейрохирургия и неврология детского возраста. 2015. № 3. С. 12–18.
19. Sokolova M., Penniyaynen V., Kipenko A. et al. Study of reinnervation process in patients with 2 type of spinal muscular atrophy: clinical experimental study // Act Nerv Super Rediviva. 2015. Vol. 57, N 4. P. 128–131. DOI: 10.17816/mechnikov20146445–51.
20. Sokolova M.G., Penniyaynen V.A., Lobzin S.V. et al. Importance of high concentration of BDNF and NGF in neurite-inhibition effect when analyzing blood serum of patients with 2 type Spinal Muscular Atrophy in organotypic tissue culture // Proceedings of the 5th International congress of myology. Lyon, 2016. Poster presentation.
21. Beeri M. S., Sonnen J. Brain BDNF expression as a biomarker for cognitive reserve against Alzheimer disease progression. 2016. Vol. 86. N8. P. 702. DOI: 10.1212/WNL.0000000000002389. PMID: 26819454.
22. Paillard T., Rolland Y., de Souto Barreto P. Protective effects of physical exercise in Alzheimer's disease and Parkinson's disease: a narrative review // Journal of clinical neurology. 2015. Vol. 11. N3. P. 212–219. PMCID: PMC4507374 DOI: 10.3988/jcn.2015.11.3.212.
23. Nguyen K.Q., Rymar V.V., Sadikot A. F. Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R 6/2 mouse model of Huntington’s disease // Frontiers in cellular neuroscience. 2016. Vol. 10. P. 37. PMID: 27013968 DOI: 10.3389/fncel.2016.00037.
24. Khan N., Smith M. T. Neurotrophins and neuropathic pain: role in pathobiology // Molecules. 2015. Vol. 20. N6. P. 10657–10688. PMID: 26065639. DOI: 10.3390/molecules200610657.
25. Libman-Sokołowska M., Drozdowicz E., Nasierowski T. BDNF as a biomarker in the course and treatment of schizophrenia // Psychiatr Pol. 2015. Vol. 49. N 6. P. 1149–1158. PMID: 26909392. DOI: 10.12740/PP/37705.
26. Youssef M. M., Underwood M. D., Huang Y. Y. et al. Association of BDNF Val66Met polymorphism and brain BDNF levels with major depression and suicide // International Journal of Neuropsychopharmacology. 2018. Vol. 21. N6. P. 528–538. PMID: 29432620. DOI: 10.1093/ijnp/pyy008.
Review
For citations:
Nalkin S.A., Sokolova M.G., Lobzin S.V., Kokorenko V.L., Vasileva N.V., Frolova E.V., Aak O.V. Generalized form and duration of myasthenia gravis as predictors of cognitive impairment. Medical alphabet. 2020;(22):60-64. (In Russ.) https://doi.org/10.33667/2078-5631-2020-22-60-64
Views:
1990
Email this article 